| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg | |||
| Other Sizes |
| Targets |
The molecular targets of 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone have not been definitively identified in publicly available literature. As an anthraquinone derivative, it may interact with various cellular targets, including enzymes, DNA, and signaling proteins, similar to other compounds in this class. Anthraquinones are known for their diverse biological activities, including anticancer, antimicrobial, and anti-inflammatory effects. Further research is needed to elucidate its specific mechanism of action and primary molecular targets.
|
|---|---|
| ln Vitro |
Specific in vitro activity data for 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone are limited in publicly available sources. As an anthraquinone compound, it may exhibit biological activities consistent with other members of this class, including antioxidant, antimicrobial, and anticancer effects. The compound's activity would be expected to be concentration-dependent, with effective concentrations typically in the micromolar range. Further studies are needed to fully characterize its in vitro potency and efficacy against specific targets or disease models.
|
| ln Vivo |
Specific in vivo efficacy data for 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone are not well-documented in publicly available sources. The compound is primarily used as a research tool for in vitro studies of anthraquinone biology. Further studies are needed to determine its pharmacokinetic properties, bioavailability, and therapeutic potential in animal models.
|
| Enzyme Assay |
The in vitro assays for 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone would depend on its hypothesized biological activity. General assays for antioxidant activity (e.g., DPPH, ABTS radical scavenging), antimicrobial activity (broth microdilution), or anticancer activity (cell viability assays using MTT or CellTiter-Glo) may be used. However, specific assay protocols for this compound are not documented in publicly available sources. Researchers would need to design appropriate assays based on the compound's chemical properties and hypothesized mechanism of action.
|
| Cell Assay |
For in vitro cellular assays, 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone would be tested in appropriate cell lines at varying concentrations (typically 0.1 to 100 µM) for 24-72 hours. Cell viability would be assessed using MTT or CellTiter-Glo assays. Specific signaling pathways would be investigated based on the compound's hypothesized mechanism of action. However, specific protocols are not documented, and researchers would need to develop appropriate assays.
|
| Animal Protocol |
In vivo studies for 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone have not been documented in publicly available sources. If in vivo studies were to be performed, the compound would likely be administered to rodents via appropriate routes (e.g., intraperitoneal, oral) at doses determined by preliminary studies. However, specific protocols are not available.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone are not available in publicly accessible literature. The compound's absorption, distribution, metabolism, and excretion have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone are not available in publicly accessible literature. The compound's safety profile has not been characterized.
|
| References | |
| Additional Infomation |
1,2,3,7-Tetrahydroxy-8-methoxy-6-methyl-9,10-anthraquinone is a naturally occurring anthraquinone compound extracted from Cassia obtusifolia seeds. It has a molecular formula of C16H12O7 and a molecular weight of 316.26. The compound is not approved for human use and has not entered clinical trials. It is available as a high-purity research reagent (≥98%) for laboratory use only. Its natural origin and anthraquinone structure make it a potential tool for studying the biological activities of anthraquinones, including their antioxidant, antimicrobial, and anticancer properties.
|
| Molecular Formula |
C16H12O7
|
|---|---|
| Molecular Weight |
316.26
|
| Exact Mass |
316.058
|
| CAS # |
130018-57-4
|
| PubChem CID |
163322626
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
2.3
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
1
|
| Heavy Atom Count |
23
|
| Complexity |
507
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC1=CC2=C(C(=C1O)OC)C(=O)C3=C(C(=C(C=C3C2=O)O)O)O
|
| InChi Key |
JXCZCRQTBVMFTA-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C16H12O7/c1-5-3-6-10(16(23-2)11(5)18)14(21)9-7(12(6)19)4-8(17)13(20)15(9)22/h3-4,17-18,20,22H,1-2H3
|
| Chemical Name |
1,2,3,7-tetrahydroxy-8-methoxy-6-methylanthracene-9,10-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.1620 mL | 15.8098 mL | 31.6196 mL | |
| 5 mM | 0.6324 mL | 3.1620 mL | 6.3239 mL | |
| 10 mM | 0.3162 mL | 1.5810 mL | 3.1620 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
